Core Viewpoint - The company has signed significant business cooperation agreements with Beijing University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][2][3]. Group 1: Joint Research Content - The research will focus on developing digital therapies and clinical applications, including the effectiveness of cognitive digital therapies for Attention Deficit Hyperactivity Disorder (ADHD) and a precision intelligent diagnosis system for depression [2]. - The research scope includes developing digital therapy products for emotional and behavioral issues across the entire lifecycle, with clinical validation for various age groups [2][3]. Group 2: Commercial Cooperation Content - The company will collaborate on digital technology services for cognitive disorder diagnosis and treatment, establishing a health management system covering elderly, children, and adults [2][3]. Group 3: Establishment of Key Laboratory - The "Beijing Key Laboratory for Precision Intelligent Diagnosis and Transformation of Mental Disorders" has been officially approved, with the company as a core co-builder [4]. - The laboratory will focus on innovation and transformation driven by clinical needs, integrating clinical medicine, basic research, technology development, and hardware innovation [4]. Group 4: Strategic Importance - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's pioneering advantage in the field of digital mental health therapies, accelerating product development and commercialization [5]. - The company aims to continue partnerships with top medical institutions to build a nationwide integrated digital mental health service system [5].
脑动极光-B(06681.HK)签订重要业务合作协议及获批精神疾病精准智能诊疗创新转化北京市重点实验室